J.M. Smucker Posts Upbeat Q3 Results; Raises Full-year View- Quick Facts

Food and beverage maker The J.M. Smucker Co. (SJM) reported its third-quarter earnings of $261.5 million or $2.32 per share, up from $187.4 million or $1.64 per share in the comparable quarter last year.

Excluding items, adjusted earnings of $2.45 per share beat the average estimate of analysts polled by Thomson Reuters at $2.19 per share. Analysts' estimates typically exclude special items.

Net sales in the quarter also increased to $2.077 billion from $1.972 billion in the same quarter a year ago. The consensus estimate was for $2 billion.

Looking forward to the full year 2021, the company raised its earnings as well sales growth outlook.

The company now expects 2021 revenue growth of 2%, up from 0% - 1% rise provided earlier and adjusted earnings per share are expected between $8.70 and $8.90 compared with prior guidance of $8.35 to $8.65.

On average 13 analysts expect the company to report earnings of $8.73 per share on revenue of $7.83 billion for the period.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings. Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning.
Follow RTT